文献速递血管炎

乌司奴单抗治疗巨细胞动脉炎的前瞻性开放标签试验

Ustekinumab for the Treatment of Giant Cell Arteritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

这项前瞻性开放标签试验评估乌司奴单抗(UST)联合24周泼尼松减量方案治疗活动性新发或复发巨细胞动脉炎(GCA)的疗效与安全性。研究提前终止,13例入组患者中仅3例(23%)达到主要终点(无泼尼松缓解),7例复发,提示该方案治疗失败率较高。

要点

  • 13例活动性GCA患者接受UST 90mg皮下注射联合24周泼尼松减量,仅3例(23%)达到无泼尼松缓解。
  • 10例(77%)未达到主要终点,其中7例在中位23周后复发,研究因复发率高提前终止。
  • 所有患者均在4周内达到疾病缓解,但维持无泼尼松缓解的比例低,发生1例严重不良事件。

核心结论

  • UST联合24周泼尼松治疗活动性GCA与较高的治疗失败率相关。

研究设计与样本

  • 前瞻性开放标签试验,计划入组20例,实际入组13例活动性新发或复发GCA患者,提前终止。
  • 所有患者接受24周泼尼松减量方案,并在基线及第4、12、20、28、36、44周皮下注射UST 90mg。

主要发现

  • 13例患者中5例(39%)为新发疾病,初始泼尼松剂量为20mg(1例)、40mg(9例)、60mg(3例)。
  • 所有患者均在基线后4周内达到疾病缓解。
  • 仅3例(23%)达到主要终点(无泼尼松缓解),10例(77%)未达到,其中7例在平均23周后复发。
  • 未达到主要终点的10例中,其余3例符合不要求ESR/CRP正常化的替代无泼尼松缓解定义。
  • 发生1例严重不良事件。

关键数值与推荐

  • 活动性疾病定义为基线前6周内存在GCA症状且ESR或CRP升高。
  • 主要终点无泼尼松缓解定义为截至第52周无复发且ESR和CRP正常化。
  • 复发定义为GCA症状复发需要加强治疗。

临床怎么用

  • UST联合24周泼尼松方案在该GCA人群中失败率高,不支持作为活动性GCA的常规治疗选择。

局限性

  • 开放标签设计,样本量小(13例)且提前终止,未达目标样本量20例。
  • 无对照组,无法与标准治疗直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of ustekinumab (UST) in giant cell arteritis (GCA). METHODS: We conducted a prospective, open-label trial of UST in patients with active new-onset or relapsing GCA. Active disease was defined as the presence of GCA symptoms and elevation of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level within 6 weeks of baseline. All patients received a 24-week prednisone taper and subcutaneous UST 90 mg at baseline and at weeks 4, 12, 20, 28, 36, and 44. The primary endpoint, prednisone-free remission, was defined as the absence of relapse through week 52 and normalization of the ESR and CRP level. Relapse was defined as the recurrence of GCA symptoms requiring treatment intensification. A sensitivity analysis excluding ESR/CRP level normalization from the prednisone-free remission definition was performed. RESULTS: The study enrolled 13 patients (target sample size 20). Enrollment was closed prematurely after 7 of the initial 10 patients relapsed. Five patients (39%) had new-onset disease. The initial prednisone doses were 20 mg (1 patient), 40 mg (9 patients), and 60 mg (3 patients). All patients entered disease remission within 4 weeks of baseline. Only 3 (23%) achieved the primary endpoint. Of the 10 patients (77%) who failed to achieve the primary endpoint, 7 relapsed after a mean period of 23 weeks. The remaining 3 patients met the alternative definition of prednisone-free remission that did not require ESR/CRP level normalization. One serious adverse event occurred. CONCLUSION: UST combined with 24 weeks of prednisone was associated with a high rate of treatment failure in this prospective GCA trial.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Matza MA, Fernandes AD, Stone JH, et al. Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res (Hoboken). 2021. PMID: 32248659. doi:10.1002/acr.24200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。